EYEN
EYEN
Eyenovia, Inc. • NASDAQ
$7.56 ▲ 3.99% (+0.29)
Market Cap $38.59 M
52w High $124.80
52w Low $0.85
Dividend Yield 0%
P/E -0.1772567409144197
Volume 29.50K
Outstanding Shares 5.10M
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 ▼ | $8.353M ▲ | $-8.691M ▼ | 0% ▲ | $-2.5 ▲ | $-8.163M ▼ |
| Q1-2025 | $14.72K ▼ | $3.045M ▼ | $-3.484M ▲ | -23.665K% ▲ | $-3.06 ▲ | $-2.902M ▲ |
| Q4-2024 | $28.093K ▲ | $16.378M ▲ | $-19.955M ▼ | -71.031K% ▲ | $-17.5 ▼ | $-19.211M ▼ |
| Q3-2024 | $1.625K ▼ | $7.201M ▼ | $-7.888M ▲ | -485.406K% ▼ | $-9.07 ▼ | $-6.998M ▲ |
| Q2-2024 | $22.625K | $8.062M | $-11.054M | -48.856K% | $-0.21 | $-10.086M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $7.532M ▲ | $55.66M ▲ | $18.301M ▲ | $37.359M ▲ |
| Q1-2025 | $3.935M ▲ | $5.984M ▲ | $15.698M ▼ | $-9.714M ▲ |
| Q4-2024 | $2.121M ▼ | $3.668M ▼ | $16.764M ▼ | $-13.096M ▼ |
| Q3-2024 | $7.188M ▲ | $22.796M ▲ | $19.077M ▼ | $3.719M ▲ |
| Q2-2024 | $2.301M | $18.995M | $21.365M | $-2.37M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-8.691M ▼ | $-3.447M ▲ | $-45.523M ▼ | $52.567M ▲ | $3.597M ▲ | $-3.47M ▲ |
| Q1-2025 | $-3.484M ▲ | $-4.443M ▲ | $0 | $6.256M ▲ | $1.814M ▲ | $-4.443M ▲ |
| Q4-2024 | $-19.955M ▼ | $-6.111M ▼ | $0 ▲ | $1.044M ▼ | $-5.067M ▼ | $-6.111M ▼ |
| Q3-2024 | $-7.888M ▲ | $-5.944M ▲ | $-1.623K ▲ | $10.833M ▲ | $4.887M ▲ | $-5.945M ▲ |
| Q2-2024 | $-11.054M | $-8.174M | $-45.748K | $2.545M | $-5.675M | $-8.22M |
Market Cap $38.59 M
52w High $124.80
52w Low $0.85
Dividend Yield 0%
P/E -0.1772567409144197
Volume 29.50K
Outstanding Shares 5.10M
About Eyenovia, Inc.
https://www.eyenovia.comEyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 ▼ | $8.353M ▲ | $-8.691M ▼ | 0% ▲ | $-2.5 ▲ | $-8.163M ▼ |
| Q1-2025 | $14.72K ▼ | $3.045M ▼ | $-3.484M ▲ | -23.665K% ▲ | $-3.06 ▲ | $-2.902M ▲ |
| Q4-2024 | $28.093K ▲ | $16.378M ▲ | $-19.955M ▼ | -71.031K% ▲ | $-17.5 ▼ | $-19.211M ▼ |
| Q3-2024 | $1.625K ▼ | $7.201M ▼ | $-7.888M ▲ | -485.406K% ▼ | $-9.07 ▼ | $-6.998M ▲ |
| Q2-2024 | $22.625K | $8.062M | $-11.054M | -48.856K% | $-0.21 | $-10.086M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $7.532M ▲ | $55.66M ▲ | $18.301M ▲ | $37.359M ▲ |
| Q1-2025 | $3.935M ▲ | $5.984M ▲ | $15.698M ▼ | $-9.714M ▲ |
| Q4-2024 | $2.121M ▼ | $3.668M ▼ | $16.764M ▼ | $-13.096M ▼ |
| Q3-2024 | $7.188M ▲ | $22.796M ▲ | $19.077M ▼ | $3.719M ▲ |
| Q2-2024 | $2.301M | $18.995M | $21.365M | $-2.37M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-8.691M ▼ | $-3.447M ▲ | $-45.523M ▼ | $52.567M ▲ | $3.597M ▲ | $-3.47M ▲ |
| Q1-2025 | $-3.484M ▲ | $-4.443M ▲ | $0 | $6.256M ▲ | $1.814M ▲ | $-4.443M ▲ |
| Q4-2024 | $-19.955M ▼ | $-6.111M ▼ | $0 ▲ | $1.044M ▼ | $-5.067M ▼ | $-6.111M ▼ |
| Q3-2024 | $-7.888M ▲ | $-5.944M ▲ | $-1.623K ▲ | $10.833M ▲ | $4.887M ▲ | $-5.945M ▲ |
| Q2-2024 | $-11.054M | $-8.174M | $-45.748K | $2.545M | $-5.675M | $-8.22M |
CEO
Michael M. Rowe
Compensation Summary
(Year 2024)
Salary $0
Bonus $0
Stock Awards $0
Option Awards $0
Incentive Plan Pay $0
All Other Compensation $0
Outstanding Value $0
Total Compensation (Unknown At The Moment)
CEO
Michael M. Rowe
Compensation Summary
(Year 2024)
Salary $0
Bonus $0
Stock Awards $0
Option Awards $0
Incentive Plan Pay $0
All Other Compensation $0
Outstanding Value $0
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public January 25, 2018
Method of going public IPO
Full time employees 13
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-02-03 | Reverse | 1:80 |
Most Recent Analyst Grades
Grade Summary
Neutral 1
Institutional Ownership
FAIRPOINTE CAPITAL LLC
209.526K Shares
$1.584M
BLACKROCK INC.
124.799K Shares
$943.48K
LEO BROKERAGE, LLC
16.112K Shares
$121.807K
HC FINANCIAL ADVISORS INC
2.5K Shares
$18.9K
AMERICAN PORTFOLIOS ADVISORS
2K Shares
$15.12K
Summary
% Of Shares Owned 6.95%
Total Number Of Holders 5
Only Showing The Top 5